By Admin at 23 May 2016

Gateway has just approved two new immunotherapy trials. A brain cancer study at MD Anderson will assess if immunotherapy can target a virus (cytomegalovirus or CMV) that is commonly found in Glioblastoma cancer cells but not in normal brain tissue. And, a pancreatic cancer study at Johns Hopkins will assess the effectiveness of combining five treatment modalities (including the promising new drug Pembrolizumab) on patients with aggressive and deadly advanced pancreatic adenocarcinoma.